Clinical Trials Logo

Filter by:
NCT ID: NCT03387592 Recruiting - Clinical trials for Neuroendocrine Carcinoma

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

SENECA
Start date: March 6, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to receive FOLFIRI or CAPTEM as second line treatment. Disease control rate (DCR) and safety are primary objectives, secondary objectives are Disease control rate (OS), Progression Free Survival (PFS), quality of life and toxicity of subsequent line of therapy (after Progression Disease PD) with an observational purpose.

NCT ID: NCT03386981 Recruiting - Physical Activity Clinical Trials

Metabolic Profile of Bone in Professional Athletes

SportMarkers
Start date: February 4, 2016
Phase: N/A
Study type: Observational

Physical activity is a key stimulus for bone metabolism through both direct mechanisms (e.g., as a result of the applied load and/or impact) and indirect mechanisms (e.g., the activation of several metabolic pathways and the production of several mediators and effectors that have systemic effects). However, different kinds of physical activity exert different effects on bone and endocrine system. Aim of the study is to investigate the effects of different kinds of physical activity on bone metabolism and on the relationships existing between bone metabolism, energy metabolism, hormone profile, and organ functionality.

NCT ID: NCT03386734 Recruiting - Cervical Cancer Clinical Trials

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

SENTICOLIII
Start date: May 3, 2018
Phase: N/A
Study type: Interventional

SENTICOL III is large prospective multicenter international randomized study designed to validate the Sentinel Lymph Node (SLN) mapping technique in early cervical cancer. This "validation study" will compare the outcome of patients with negative SLN (experimental arm) vs patients with negative SLN + Pelvic Lymph Node dissection (PLN)(reference arm). There will be a "quality assurance" program which will be developed in participating centers with detailed requirements in terms of surgeons' qualifications, pathology qualification, SLN ultrastaging, standardization of the procedure, etc. as well as respect of the "safety algorithm".

NCT ID: NCT03386370 Recruiting - Clinical trials for Acute Ischemia of Lower Limb

The Indigo System in Acute Lower Limb Malperfusion

INDIAN
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

To evaluate, in a controlled setting, the early safety and effectiveness of the Penumbra/Indigo aspiration thrombectomy Systems (San Francisco, California), and to define optimal technique for the use of these systems in patients with confirmed peripheral acute occlusions.

NCT ID: NCT03382366 Recruiting - Sarcopenia Clinical Trials

Sarcopenia and Risk of Fall in Osteoporotic Postmenopausal Women

Sarcopenia
Start date: March 29, 2017
Phase: N/A
Study type: Interventional

The main scope of the present pilot study is to evaluate the possible association between the status of sarcopenia and the risk of fall in osteoporotic postmenopausal women. Forty osteoporotic postmenopausal women, previously (pre-recruitment) classified by DXA in 20 sarcopenic and 20 non-sarcopenic subjects, will be recruited. The investigators will collect data on: 1) bone (vitamin D) and muscle (myokines) metabolisms through blood sampling; 2) Risk of fall by the OAK device produced by Khymeia; 3) thigh muscle quality through MR.

NCT ID: NCT03380858 Recruiting - Colorectal Cancer Clinical Trials

REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis

ANASTOSEAL
Start date: November 2, 2017
Phase: N/A
Study type: Observational

In colorectal surgery about 30% of postoperative mortality is attributed to anastomotic leak, whit an incidence range between 1.8% and 15.9%. Preventing the anastomotic leak can therefore bring benefits to the patient and the health system. To date we have technologically advanced suturizers and the correct realization (well-vascularized margins, not in tension, etc.) remains crucial to prevent anastomotic dehiscence. Experimental results demonstrate that modified cyanacrylate is a suitable potential "reinforcement" on intestinal anastomoses (manual or linear intra-corporeal). Applied after mechanical anastomosis, it polymerizes in a short time, closing the spaces of the suture line between one point and the other, expressing an adhesive, hemostatic and sealing action on the tissues, also creating an effective antiseptic barrier towards of the most common infectious or pathogenic agents.

NCT ID: NCT03377829 Recruiting - Thyroid Cancer Clinical Trials

A Multicenter Trial of PLA vs. Surgery for Treating PTMC

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

This is a multicenter prospective controlled trial of percutaneous laser ablation(PLA) versus conventional surgery for the treatment of papillary thyroid microcarcinoma (PTMC).

NCT ID: NCT03375125 Recruiting - Clinical trials for Periodontitis and Pregnancy

L. Reuteri ATCC PTA 5289 + L. Reuteri DSM 17938 in Pregnant Women

Start date: December 20, 2017
Phase: N/A
Study type: Interventional

Randomized controlled tril to evaluate the safety and efficacy for the combination of L. reuteri ATCC PTA 5289 & L. reuteri DSM 17938 in pregnant women with periodontitis and/or gingivits to improve oral health and at the same time reduce the risk for prematurity or intrauterine growth retardation (IUGR). Women in this study wil receive L. reuteri Prodentis (L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 ) at a dose of 2x10^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day since randomization until delivery. The control group will receive placebo lozenges which contains identical ingredients except for lacking the bacteria. One lozenges is to be taken twice per day (one in the morning and one in the afternoon. The study product will be kept refrigerated (+20 - +80 C)

NCT ID: NCT03374033 Recruiting - Clinical trials for Infant, Very Low Birth Weight

High Protein and High Energy Intakes and Physical Activity on Growth of Extremely Low Birth Weight Infants

Start date: April 10, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of increasing amino acid and energy intake during parenteral and enteral nutrition with and without the stimulation of the infant's physical activity, on growth of extremely low birth weight infants .

NCT ID: NCT03373097 Recruiting - Sarcoma Clinical Trials

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Start date: January 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma. A small exploratory cohort of patients with GD2-positive tumors other than Neuroblastoma has also been included.